We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Short Synthetic Probes Utilized for Bladder Cancer Diagnosis

By LabMedica International staff writers
Posted on 08 Jul 2010
A novel assay has been developed to test for multiple tumor markers in bladder cancer.

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) can be used to screen multiple target sequences simultaneously in a single reaction, allowing for rapid early screening of tumor markers.

Commercially available MS-MLPA kits are not available for many diseases, and custom probe design has been limited by problems of chemically synthesizing longer nucleotides. More...
Dr. Per Guldberg of the Danish Cancer Society (Copenhagen, Denmark) and colleagues from the Herlev University Hospital (Copenhagen, Denmark) have modified this assay by using multiple short synthetic probes to test for tumor markers in bladder cancer. They found that paired tumor and urine samples in most cases showed identical marker patterns, suggesting that this assay may be used for noninvasive diagnosis and disease monitoring.

The study was published in the July 2010 edition of the Journal of Molecular Diagnostics. The authors suggested, "The use of multiple short synthetic probes may provide a simple and cost-effective approach to custom-designed MLPA." In future studies, Dr. Guldberg's group will examine how "the same approach may be used for most other MLPA applications and thus provide the basis for a more widespread usage of the MLPA technology."

Related Links:
Danish Cancer Society
Herlev University Hospital



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.